Abstract
All-trans retinoic acid (ATRA), alone or combined with chemotherapy (CHT) is widely used to induce complete remission (CR) in newly diagnosed acute promyelocytic leukemia (APL). If used alone, ATRA results in a substantial proportion of CRs. To maintain remission further, ATRA is commonly used with cycles of CHT, frequently followed by autologous (auto) or allogeneic (allo) stem cell transplantation (SCT), as early reports have shown that the continuous administration of ATRA as single therapy almost invariably leads to relapse in a short period of time (months). Pharmacokinetic studies have shown that induced resistance to ATRA is frequently suppressed by the intermittent use of the drug. In this study we applied an intermittent therapeutic protocol with ATRA in five APL patients who were either molecularly refractory after combined ATRA/CHT treatment, or relapsed, or at diagnosis, but not eligible for the combination treatment because of previous toxicity. They were treated with ATRA (45 mg/m2/day) for 21 days. The treatment was then prolonged continuously for 1 week every 2 weeks. Molecular analysis was performed by qualitative and quantitative reverse transcription-polymerase chain reaction (RT-PCR). All patients obtained molecular remission, as assessed by qualitative RT-PCR, in a median of 3 months (range 1–15). Quantitative RT-PCR confirmed these data, showing a progressive reduction (1 or 2 logs) to a ‘negligible quantity’ of PML-RARα fusion transcript (ratio PML-RARα/ABL × 104 ABL < 10−1) in all but one patient treated with pulsed ATRA therapy. These data were confirmed with qualitative and quantitative RT-PCR. After a median follow-up of 17 months from the start of ATRA therapy, 4/5 patients (80%) are in continuous complete molecular remission. To our knowledge, this is the first clinical observation that intermittent ATRA therapy (without chemotherapy) is effective not only in inducing but also in maintaining long-term molecular remission in APL patients. This approach could therefore be effective, if confirmed in larger series, in relapsed/refractory patients unsuitable for high-dose therapy and SCT; it may be proposed as induction therapy for selected older APL patients if considered not to be eligible for combined ATRA/CHT due to inadequate performance status or concurrent disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
De Thè H, Chomienne C, Lanotte M, Degos L, Dejean A . The t(15;17) of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus Nature 1990 347: 558–561
De Thè H, Lavau C, Marcio A, Chomienne C, Degos L Dejean A . The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR Cell 1991 66: 675–684
Kakizuka A, Miller WH Jr, Umesono K, Warrel RP Jr, Frankel SR, Murty VVVS, Dmitrowsky E, Evans RM . Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor, PML Cell 1991 66: 663–674
Grignani F, Ferruci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG . The acute promyelocytic leukemia-specific PML-RAR-alpha fusion protein inhibits differentiation and promotes survival of myeloid percursor cells Cell 1993 74: 423–431
Visani G, Tosi P, Ottaviani E, Zaccaria A, Baccini C, Manfroi S, Pastano R, Remiddi C, Morelli A, Molinar AL, Zanchini R, Tura S . All trans retinoid acid and in vitro cytokine production by acute promyelocytic leukemia cells Eur J Haematol 1996 57: 301–306
Miller WH Jr, Kakizuka A, Frankel SR, Warrel RP Jr, DeBlasio A, Levine K, Evans RM, Dmitrowsky E . Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia Proc Natl Acad Sci USA 1992 89: 2694–2698
Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrowsky E, Warrel RP Jr . Detection of minimal residual disease in acute promyelocytic leukemia by a reverse trancription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA Blood 1993 82: 1689–1694
Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti Meloni G . Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia Lancet 1992 340: 1437–1438
Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG . Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood 1999 94: 12–22
Holland PM, Abramson RD, Watson R, Gelfand DH . Detection of specific polymerase chain reaction product by utilizing the 5′ → 3′ exonuclease activity of Thermus aquaticus DNA polymerase Proc Natl Acad Sci USA 1991 88: 7276–7280
Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrowsky E . Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid) N Engl J Med 1991 324: 1385–1393
Delva L, Cornic M, Balitrand N, Guidez F, Miclea J-M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C . Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells Blood 1993 82: 2175–2181
Visani G, Gugliotta L, Tosi P, Catani L, Vianelli N, Martinelli G, Ottaviani E, Testoni N, Nocentini F, Pastano R, Piccaluga PP, Isidori A, Grafone T, Tura S . All trans retinoic acid significantly reduces the incidence of early hemorrhagic deaths during induction therapy of acute promyelocytic leukemia Eur J Haematol 2000 64: 139–144
Breitman T, Collins SJ, Keene BR . Terminal differentiation of promyelocytic leukemia cells in primary cultures in response to retinoic acid Blood 1981 57: 1000–1004
Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG . Acute promyelocytic leukemia: from genetics to treatment Blood 1994 83: 10–25
Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L . All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Clinical results Blood 1990 76: 1704–1709
Ding W, Li YP, Nobile LM, Grills G, Carrera I, Tallman MS, Wiernik PH, Gallagher RE . Retinoic acid receptor alpha (RAR-α)-region mutations in the PML-RARα fusion gene of acute promyelocytic leukemia (APL) patients after relapse from all-trans retinoic acid (ATRA) therapy Blood 1997 90 (Suppl. 1): 415a
Jurcic JG, Miller WH, DeBlasio A, Scheinberg DA, Warrell RP Jr . Prognostic significance of minimal residual disease detection and PML-RARα isoform type: long term follow-up in acute promyelocytic leukemia (APL) Blood 1996 88 (Suppl. 1): 635a
Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rosi V, Avvisati G, Rambaldi A, Arcese W, Petti M C, Meloni G . Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia Lancet 1992 12: 1437–1438
Degos L, Dombret H, Chomienne C, Daniel M-T, Miclea J-M, Chastang C, Castaigne S, Fenaux P . All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia Blood 1995 85: 2643–2653
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F . Molecular remission in PML/RARα–positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy Blood 1997 90: 1014–1021
Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F . AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study Blood 1996 88: 1390–1398
Martinelli G, Ottaviani E, Testoni N . Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript Haematology 2000 85: 552–555
Van Dongen JM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Perreira A, Gameiro P, Gonzàlez Diaz M, Malec M, Longerak AW, San Miguel JF, Biondi A . Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for minimal residual disease Leukemia 1999 13: 1901–1928
Marcucci G, Livk K, Bi W, Strout MP, Bloomfield CD, Caligiuri MA . Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay Leukemia 1998 12: 1482–1489
Gabert J, Beillard E, Pallisgaard N, Gottardi E, Cazzaniga G, Barbany G, Cavè H, Cayuela JM, Grimwade D, Aerts J, van Den Velden V, Pane F, Saglio G, van Dongen JJM . European standardization and quality control program of real time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukemia patients Blood 2000 96 (Suppl. 1): 311a
Acknowledgements
This work was supported in part by MURST ex 60% (S Tura) and FONDI ex 40% (S Tura)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Visani, G., Buonamici, S., Malagola, M. et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 15, 1696–1700 (2001). https://doi.org/10.1038/sj.leu.2402266
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402266
Keywords
This article is cited by
-
Retinoid Chemoprevention: Who Can Benefit?
Current Pharmacology Reports (2015)
-
Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
Leukemia (2003)
-
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
Leukemia (2003)
-
Monitoring PML-RARα in acute promyelocytic leukemia
Current Oncology Reports (2003)
-
Monitoring minimal residual disease in AML: the right time for real time
Annals of Hematology (2003)